Showing 481 - 500 results of 225,005 for search '(( a ((mean decrease) OR (a decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 1.67s Refine Results
  1. 481
  2. 482
  3. 483
  4. 484
  5. 485
  6. 486

    mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes. by Wakiko Iwata (8600457)

    Published 2020
    “…<p>(<b>A</b>) Primary cultured podocytes were isolated from <i>Tsc2</i><sup>Δ<i>podocyte</i></sup> and wild-type controls, followed by western blot analyses of TSC2, phospho-4EBP1, LC3B type II, p62, phospho-ULK1, and β-tubulin. …”
  7. 487
  8. 488
  9. 489
  10. 490
  11. 491

    (+)-Usnic acid decreases β-catenin-mediated TOPFLASH activity and KITENIN-mediated AP-1 activity. by Yi Yang (116183)

    Published 2016
    “…<p>(A) β-Catenin-mediated transcriptional activity of TOPFLASH promoter was decreased by (+)-usnic acid treatment. …”
  12. 492

    Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository by Fidéline Bonnet-Serrano (4782546)

    Published 2018
    “…Results were expressed as mean ±SD.</p><p>Results</p><p>An automated quantification method was set up using the R software and was validated by quantification of β-cell mass, a well characterized parameter. β-cell mass was 29.6±112 mg in patients and 628 ±717 mg in controls (p<0.0001). α-cell mass was 181±176 mg in patients and 349 ±241mg in controls (p<0.0001). …”
  13. 493
  14. 494
  15. 495
  16. 496
  17. 497
  18. 498
  19. 499

    <i>TERT-CLPTM1L</i> Rs401681 C>T Polymorphism Was Associated with a Decreased Risk of Esophageal Cancer in a Chinese Population by Jun Yin (94374)

    Published 2014
    “…</p><p>Results</p><p>When the <i>TERT-CLPTM1L</i> rs401681 CC homozygote genotype was used as the reference group, the CT genotype was associated with a significantly decreased risk of ESCC (adjusted OR  = 0.74, 95% CI  = 0.58–0.94, <i>p</i> = 0.012); the CT/TT variants were associated with a 26% decreased risk of ESCC (adjusted OR  = 0.74, 95% CI  = 0.59–0.93, <i>P</i> = 0.009). …”
  20. 500